Management of Patients with Sustained Ventricular Tachyarrhythmias: Different Clinical Studies, Different Patients

  • M. Borggrefe
  • W. Haverkamp
  • A. Martinez-Rubio
  • T. Wichter
  • G. Breithardt
Chapter

Abstract

In the United States, approximately 350 000 patients each year die from sudden cardiac death. Based on results of Holier monitoring recordings at the time of sudden death, approximately 80 % of deaths are due to ventricular tachyarrhythmias [1–3]. In addition, approximately 3–6% of postmyocardial infarction patients develop monomorphic ventricular tachycardia that does not lead to cardiac arrest. Thus, overall, approximately 400 000 patients each year develop potentially life-threatening sustained ventricular tachyarrhythmias. Most commonly, these arrhythmias are encountered in patients with coronary artery disease and cardiomyopathies. Based on observations back to the 1930 s, patients with sustained ventricular tachyarrhythmias have a high mortality rate. Management of sustained ventricular tachyarrhythmias can be divided into two main categories: pharmacological and non-pharmacological. The pharmacological approach remains by far the most commonly used mode of therapy, at least for a first attempt.

Keywords

Catheter Radionuclide Stratification Fibril Cardiomyopathy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kempf FC, Josephson ME (1984) Cardiac arrest recorded on ambulatory electrocardiograms. Am J Cardiol 53: 1577–1582PubMedCrossRefGoogle Scholar
  2. 2.
    Pratt CM, Francis MJ, Luck JC (1983) Analysis of ambulatory electrocardiograms in 15 patients during spontaneous ventricular fibrillation with special reference to preceding arrhythmic events. J Am Coll Cardiol 2: 789–797PubMedCrossRefGoogle Scholar
  3. 3.
    De Luna AB, Coumel P, Leclercq JF (1989) Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmias on the basis of data from 157 cases. Am Heart J 117: 151–159CrossRefGoogle Scholar
  4. 4.
    Cobb LA, Baum RS, Alvarez H (1975) Resuscitation from out-of-hospital ventricular fibrillation: 4 years follow-up. Circulation 52: 223–229Google Scholar
  5. 5.
    Trappe HJ, Brugada P, Talajic M, Della Bella P, Lezaun R, Mulleneers R, Wellen JHH (1988) Prognosis of patients with ventricular tachycardia and ventricular fibrillation: role of the underlying etiology. J Am Coll Cardiol 12: 166–174PubMedCrossRefGoogle Scholar
  6. 6.
    Leclercq JF, Coumel P, Denjoy I, Maisonblanche P, Cauchemez B, Chourty F, Leenhardt A, Slama R (1991) Long-term follow-up after sustained monomorphic ventricular tachycardia: caues, pump failure, and empiric antiarrhythmic therapy that modify survival. Am Heart J 121:1685–1692Google Scholar
  7. 7.
    Hallstrom AP, Cobb LA, Yu BH, Weaver WD, Fahrenbruch CE (1991) An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol 68: 1025–1031PubMedCrossRefGoogle Scholar
  8. 8.
    Willems AR, Tussen JG, Van Capelle FJ, Kingma JH, Hauer RN, Vermeulen FE, Brugada P, Van Hoogenhuyze DC, Janse MJ on behalf of the Dutch Ventricular Tachycardia Study Group of the Interuniversity Cardiology Institute of The Netherlands (1990) Determinants of prognosis in symptomatic ventricular tachycardia or ventricular fibrillation late after myocardial infarction. J Am Coll Cardio116: 521–530Google Scholar
  9. 9.
    Lampert S, Lown B, Graboys TB, Podrid PJ, Blatt CM (1988) Determinants of survival in patients with malignant ventricular arrhythmia associated with coronary artery disease. Am J Cardiol 61: 791–797PubMedCrossRefGoogle Scholar
  10. 10.
    Graboys TB, Lown B, Podrid PJ, De Silva R (1982) Long-term surival of patients with malignant ventricular arrhythmias treated with antiarrhythmic drugs. Am J Cardiol 50: 438–443CrossRefGoogle Scholar
  11. 11.
    Baum RS, Alvarez H, Cobb LA (1974) Survival after resuscitation from out-of-hospital ventricular fibrillation. Circulation 50: 1231–1235PubMedCrossRefGoogle Scholar
  12. 12.
    Myerburg RJ, Kessler KM, Estes D, Conde CA, Luceri RM, Zaman L, Koslovskis PL, Castellanos A (9184) Long-term survival after pre-hospital cardiac arrest. Analysis of outcome during 8 years study. Circulation 70: 538–546Google Scholar
  13. 13.
    Wilber DJ, Garan H, Finkelstein D, Kelly E, Newell J, McGovern B, Ruskin JN (1988) Outof-hospital cardiac arrest–use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med 318: 19–24PubMedCrossRefGoogle Scholar
  14. 14.
    Furukawa T, Rozanski JJ, Nogami A, Moroe K, Gosselin AJ, Lister JW (1989) Time-dependent risk of and predictors for cardiac arrest recurrences in survivors of out-of-hospital cardiac arrest with chronic coronary artery disease. Circulation 80: 599–608PubMedCrossRefGoogle Scholar
  15. 15.
    Rodriguez LM, Smeets J, O’Hara GE, Geelen P, Brugada P, Wellen HJJ (1992) Incidence and timing of recurrences of sudden death and ventricular tachycardia during antiarrhythmic drug treatment after myocardial infarction. Am J Cardiol 69: 1403–1406PubMedCrossRefGoogle Scholar
  16. 16.
    Bardy GH, Hofer B, Johnson G (1993) Implantable transvenous cardioverter-defibrillators. Circulation 87: 1152–1168PubMedCrossRefGoogle Scholar
  17. 17.
    Leitch JW, Gillis AM, Wyse DG (1991) Reduction in defibrillator shocks with an implantable device combining antitachycardia pacing and shock therapy. J Am Coll Cardiol 18: 145–151PubMedCrossRefGoogle Scholar
  18. 18.
    Siebels J, Cappato R, Ruppel R (1993) ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study, Hamburg. PACE 16: 552–558Google Scholar
  19. 19.
    Böcker D, Block M, Isbruch F, Wietholt D, Hammel D, Borggrefe M, Breithardt G (1993) Do patients with an implantable defibrillator live longer? J Am Coll Cardiol 21: 1638–1644PubMedCrossRefGoogle Scholar
  20. 20.
    The Cardiac Arrhythmia Suppression Trial Investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406–410CrossRefGoogle Scholar
  21. 21.
    Prystowsky EN (1988) Electrophysiologic-electropharmacologic testing in patients with ventricular arrhythmias. PACE ií: 225–251Google Scholar
  22. 22.
    Waldo AL, Akthar M, Brugada P (1985) The minimally appropriate electrophysiologic study for the initial assessment of patients with documented sustained monomorphic ventricular tachycardia. J Am Coll Cardiol 6: 1174PubMedCrossRefGoogle Scholar
  23. 23.
    Borggrefe M, Trampisch HI, Breithardt G (1988) Reappraisal of criteria for assessing drug efficacy in patients with ventricular tachyarrhythmias: complete versus partial suppression of inducible arrhythmias. J Am Coll Cardio112: 140–149Google Scholar
  24. 24.
    Waller TJ, Kay HR, Spielman SR (1987) Reduction in sudden death and total mortality by antiarrhythmic therapy evaluated by electrophysiologic drug testing: criteria of efficacy in patients with sustained ventricular tachyarrhythmia. J Am Coll Cardiol io: 83–89Google Scholar
  25. 25.
    Borggrefe M, Breithardt G (1986) Predictive value of electrophysiologic testing in the treatment of drug-refractory ventricular arrhythmias with amiodarone. Eur Heart J 7:742Google Scholar
  26. 26.
    Hammer AW, Finerman WB, Peter T, Mandel WJ (1981) Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias. Am Heart J 102: 992–1000CrossRefGoogle Scholar
  27. 27.
    Nademanee K, Hendrickson J, Kannon R, Singh BN (1982) Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. Am Heart J 103: 950–959PubMedCrossRefGoogle Scholar
  28. 28.
    Heger JJ, Prystowsky EN, Jackman WM, Naccarelli GV, Warfel KA, Rinkenberger RL, Zipes DP (1981) Amiodarone. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 305: 539–545Google Scholar
  29. 29.
    Morady F, Scheinman MM, Hess DS (1983) Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation. PACE 6: 609–615PubMedCrossRefGoogle Scholar
  30. 30.
    McGovern B, Garan H, Malaroff RF, DiMarco JP, Grant G, Sellers TD, Ruskin JN (1984) Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. Am J Cardiol 53: 1558–1563PubMedCrossRefGoogle Scholar
  31. 31.
    Horowitz LN, Greenspan AM, Spielman SR, Webb CR, Morganroth J, Rotmensch H, Sokoloff NM, Rae AP, Segal BL, Kay HR (1985) Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. Am J Cardiol 55: 367–371PubMedCrossRefGoogle Scholar
  32. 32.
    Swerdlow CD, Winkle RA, Mason JW (1983) Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 308: 1436–1442PubMedCrossRefGoogle Scholar
  33. 33.
    Waxman HL, Buxton AE, Sadowski LM (1982) The response to procainamide during electrophysiologic study for sustained ventricular tachyarrhythmias predicts the response to other medications. Circulation 67: 30–37CrossRefGoogle Scholar
  34. 34.
    Horowitz LN, Josephson ME, Farshidi A (1978) Recurrent sustained ventricular tachycardia. 3. Role of the electrophysiologic study in selection of antiarrhythmic regimens. Circulation 58: 986–997Google Scholar
  35. 35.
    Mason JW, Winkle RA (1980) Accuracy of the ventricular tachycardia induction study for predicting long-term efficacy and inefficacy of antiarrhythmic drugs. N Engl J Med 303: 1073–1077PubMedCrossRefGoogle Scholar
  36. 36.
    Steinbeck G, Andresen D, Bach P (1992) A comparison of electrophysiological guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic sustained ventricular tachyarrhythmias. N Engl J Med 327: 987–992PubMedCrossRefGoogle Scholar
  37. 37.
    Mason JW, Winkle RA (1978) Electrode catheter arrhythmia induction in the selection and assessment of antiarrhythmic drug therapy for recurrent ventricular tachycardia. Circulation 58: 971–985PubMedCrossRefGoogle Scholar
  38. 38.
    Ruskin JN, DiMarco JP, Garan H (1980) Out-of-hospital cardiac arrest: electrophysiologic observations and selection of long-term antiarrhythmic therapy. N Engl J Med 303: 607–613PubMedCrossRefGoogle Scholar
  39. 39.
    Horowitz LN, Spielman SR, Greenspan AM, Josephson ME (1982) Role of programmed stimulation in assessing vulnerability to ventricular arrhythmias. Am Heart J 103: 604–610PubMedCrossRefGoogle Scholar
  40. 4o.
    Skale BT, Miles WM, Heger JJ (1986) Survivors of cardiac arrest: prevention of recurrence by drug therapy as predicted by electrophysiologic testing or electrocardiographic monitoring. Am J Cardiol 57: 113–119PubMedCrossRefGoogle Scholar
  41. 41.
    Podczeck A, Borggrefe M, Bartels K, Breithardt G (1989) Efficacy of flecainide in pacing-induced sustained ventricular tachyarrhythmias: correlation to clinical parameters and tachycardia characteristics. Eur Heart J 1o: 928–934Google Scholar
  42. 42.
    Budde T, Borggrefe M, Podczeck A, Martinez-Rubio A, Breithardt G (1991) Acute and long-term efficacy of oral propafenone in patients with ventricular tachyarrhythmias. J Cardiovasc Pharmacol 18: 254–260PubMedCrossRefGoogle Scholar
  43. 43.
    Veltri EP, Reid PR, Platia EV, Griffith LSC (1985) Results of late programmed electrical stimulation and long-term electrophysiologic effects of amiodarone therapy in patients with refractory ventricular tachycardia. Am J Cardiol 55: 375–379PubMedCrossRefGoogle Scholar
  44. 44.
    Hafferje CI, Gold RL, Yazaki Y, Sloan K, Alpert JS (1986) Electrophysiologic predictors of long-term outcome with amiodarone for refractory ventricular tachycardia. J Am Coll Cardiol 7: 109Google Scholar
  45. 45.
    Lavery D, Saksena S, Gordon S, Rothbart ST, Barr MJ (1986) Long-term efficacy of amiodarone therapy in refractory sustained ventricular tachycardia: the role of electrophysiologic studies and ambulatory monitoring. J Am Coll Cardiol 7: 91CrossRefGoogle Scholar
  46. 46.
    Klein LA, Fineberg NS, Heger JJ (1985) Amiodarone: prospective evaluation of a discriminant function to predict recurrence of ventricular arrhythmias. Circulation 72: 273Google Scholar
  47. 47.
    Cobbe SM, Alexopoulos D, Winner SJ, McCaie CP, Cobbe PC, Johnston J (1988) A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction. Eur Heart J 9: 24–31PubMedGoogle Scholar
  48. 48.
    Echt DS, Berte LE, Clusin WT, Samuelsson RG, Harrison DC, Mason JW (1982) Prolongation of the human cardiac monophasic action potential by sotalol. Am J Cardiol 5o: 1082–1086CrossRefGoogle Scholar
  49. 49.
    Senges J, Lengfelder W, Jauernig R, Czysan E, Brachmann J, Rizos I, Cobbe S, Kühler W (1984) Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. Circulation 69: 577–584PubMedCrossRefGoogle Scholar
  50. 5o.
    Nademanee K, Feld G, Hendrickson J, Singh PN, Singh BN (1985) Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 72: 555–564PubMedCrossRefGoogle Scholar
  51. 51.
    Steinbeck G, Bach P, Haber’ R (1986) Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram. J Am Coll Cardiol 8: 949–958PubMedCrossRefGoogle Scholar
  52. 52.
    Goniales R, Scheinman MM, Herre JM, Griffin JC, Sauve MJ, Sharkey H (1988) Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. J Am Coll Cardiol 12: 1568–1672CrossRefGoogle Scholar
  53. 53.
    Zheutlin T, Mattioni T, Chokshi S, Nazari J, Dunnington C, Parker M, Nebergall N, Kehoe R (1988) Sotalol for sustained ventricular tachyarrhythmias: predictors of arrhythmic outcome. J Am Coll Cardiol 1: 55Google Scholar
  54. 54.
    Ruder MA, Ellis T, Lebsack C, Mead RH, Smith NA, Winkle RA (1989) Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmia. J Am Coll Cardiol 13: 145–152PubMedCrossRefGoogle Scholar
  55. 55.
    Trappe HJ, Klein H, Lichtlen PR (1989) Antiarrhythmic efficacy of oral sotalol in patients with sustained ventricular tachycardia or ventricular fibrillation post myocardial infarction. J Electrophysiol 3: 95–100CrossRefGoogle Scholar
  56. 56.
    Jordaens LJ, Palmer A, Clement DL (1989) Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. Eur Heart J 10: 218–226PubMedGoogle Scholar
  57. 57.
    Kuchar DL, Garan H, Venditti FJ, Finkelstein D, Rottman JN, McComb J, McGovern BA, Ruskin JN (1989) Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. Am J Cardiol 64: 33–36PubMedCrossRefGoogle Scholar
  58. 58.
    Borggrefe M, Breithardt G (199o) Holier monitoring versus programmed stimulation. Cardiovasc Drugs Ther 4: 555–558Google Scholar
  59. 59.
    Kehoe R, Zheutlin T, Dunnigton C, Mattioni T, Yu G, Spangenberg R (199o) Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. Am J Cardiol 65: 55–64Google Scholar
  60. 6o.
    Nademanee K, Singh BN (199o) Effects of sotalol on ventricular tachycardia and fibrillation produced by electrical stimulation: comparison with other antiarrhythmic agents. Am J Cardiol 65: 53–57Google Scholar
  61. 61.
    Borggrefe M, Hief C, Chen X, Breithardt G (199o) Dose-dependent effects of sotalol in patients with ventricular tachycardia/fibrillation. PACE Pacing Clin Electrophysiol 12: 454Google Scholar
  62. 62.
    Kleiman RB, Miller JM, Buxton AE, Josephson ME, Marchlinski FE (1988) Prognosis following sustained ventricular tachycardia occurring early after myocardial infarction. Am J Cardiol 62: 528–533PubMedCrossRefGoogle Scholar
  63. 63.
    Kavanagh KM, Wyse DG, Duff HJ, Gillis AM, Sheldon RS, Mitchell LB (1991) Drug therapy for ventricular tachyarrhythmias: how many electropharmacologic trials are appropriate? J Am Coll Cardiol 17: 397–396CrossRefGoogle Scholar
  64. 64.
    Hii JT, Traboulsi M, Mitchell LB, Wyse DG, Duff HJ, Gillis AM (1993) Infarct artery patency predicts outcome of serial electropharmacological studies in patients with malignant ventricular tachyarrhythmias. Circulation 87: 764–772PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • M. Borggrefe
  • W. Haverkamp
  • A. Martinez-Rubio
  • T. Wichter
  • G. Breithardt

There are no affiliations available

Personalised recommendations